CLEO Diagnostics Ltd (AU:COV) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cleo Diagnostics Ltd is expanding its ovarian cancer trial with the inclusion of Siles Health, a leading women’s health specialist network in Australia. This collaboration aims to enhance clinical insights and support market adoption of CLEO’s innovative blood test for early ovarian cancer detection. By integrating Siles Health’s expertise, CLEO is poised to advance its trial strategy and increase market awareness for its potentially life-saving diagnostic tool.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘It’s Not Too Late to Load Up,’ Says Lance Vitanza About MicroStrategy Stock
- Near-Term Credit May Be a New Problem for Paramount (NASDAQ:PARA)
- Ford (NYSE:F) Lands a Huge Win at Nurburgring
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
